Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Warden, Bruce A., Kaufman, Tina, Minnier, Jessica, Duell, P. Barton, Fazio, Sergio, Shapiro, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Focus Issue on Heart Failure
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/
https://www.ncbi.nlm.nih.gov/pubmed/34317250
http://dx.doi.org/10.1016/j.jaccas.2019.09.026
Descripción
Sumario:Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. (Level of Difficulty: Advanced.)

Ejemplares similares